Chemoinformaics analysis of 1-(4-Hydroxybenzoyl)-6,7-dimethoxyisoquinoline
| Molecular Weight | 309.321 | nRot | 4 |
| Heavy Atom Molecular Weight | 294.201 | nRig | 18 |
| Exact Molecular Weight | 309.1 | nRing | 3 |
| Solubility: LogS | -3.773 | nHRing | 1 |
| Solubility: LogP | 2.635 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 38 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 2 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 15 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 18 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 17 |
| nHA | 5 | APOL | 44.3699 |
| nHD | 1 | BPOL | 20.5281 |
| QED | 0.75 |
| Synth | 2.07 |
| Natural Product Likeliness | 0.295 |
| NR-PPAR-gamma | 0.014 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.006 |
| Pgp-sub | 0.002 |
| HIA | 0.005 |
| CACO-2 | -4.744 |
| MDCK | 0.000019 |
| BBB | 0.26 |
| PPB | 0.960068 |
| VDSS | 0.735 |
| FU | 0.0261016 |
| CYP1A2-inh | 0.894 |
| CYP1A2-sub | 0.909 |
| CYP2c19-inh | 0.734 |
| CYP2c19-sub | 0.094 |
| CYP2c9-inh | 0.513 |
| CYP2c9-sub | 0.883 |
| CYP2d6-inh | 0.123 |
| CYP2d6-sub | 0.857 |
| CYP3a4-inh | 0.715 |
| CYP3a4-sub | 0.479 |
| CL | 11.336 |
| T12 | 0.804 |
| hERG | 0.268 |
| Ames | 0.855 |
| ROA | 0.22 |
| SkinSen | 0.19 |
| Carcinogencity | 0.855 |
| EI | 0.308 |
| Respiratory | 0.895 |
| NR-Aromatase | 0.891 |
| Antiviral | Yes |
| Prediction | 0.816391 |